Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy.
J Neurophysiol · 2025
Last updated 2026-05-28In a study of 24 people with diabetic peripheral neuropathy, those who took GLP-1 drugs like semaglutide or dulaglutide for 3 months showed improvements in nerve function. Clinical neuropathy scores dropped from 3.7 to 2.3, and nerve signal strength increased from 11.9 to 14.2 microvolts. The results suggest these drugs may help restore nerve function by improving how nerves use energy.
AI summary of the abstract below.
| Journal | J Neurophysiol, 2025 |
|---|---|
| Citations | 6 |
| Relative citation ratio | 2.73 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Diabetic peripheral neuropathy (DPN) affects approximately half of the 500 million people with type 2 diabetes worldwide. Previous studies have suggested that glucagon-like peptide-1 (GLP-1) receptors in the peripheral nervous system may be a suitable target for DPN treatment. Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes. Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy. These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken. Clinical neuropathy scores improved at 3 mo following commencement of GLP-1 (baseline TNS 3.7 ± 4.5, posttreatment TNS 2.3 ± 3.4, = 0.005). Nerve conduction studies demonstrated an improvement in sural amplitude at 3 mo (baseline 11.9 ± 8.5 μV, posttreatment 14.2 ± 9.2 μV; = 0.013). Axonal excitability studies revealed changes consistent with improvements in Na/K-ATPase pump function and Na permeability, and this was supported by mathematical modeling. GLP-1RA therapy improves clinical and neurophysiological outcomes in DPN. Treatment with GLP-1RA may reverse axonal dysfunction by improving Na/K-ATPase pump function. Diabetic peripheral neuropathy is known to be relentlessly progressive and irreversible. Prospective studies in 24 participants with diabetic peripheral neuropathy (DPN) treated with glucagon-like peptide-1 receptor agonists (GLP-1RA) demonstrated improvements in clinical neuropathy scores, nerve conduction studies, and axonal excitability recordings. Analysis of axonal excitability recordings revealed the mechanism for GLP-1RA improvement in DPN were changed consistent with improvements in Na/K-ATPase pump function, and this was supported by mathematical modeling.
Verbatim abstract via PubMed 39584713 ↗